Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenocarcinoma × Irinotecan × Clear all

Phase

Phase 2 7 Phase 1 4 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 31 Pancreatic Neoplasms 14 Colonic Neoplasms 11 Stomach Neoplasms 9 Rectal Neoplasms 9 Neoplasms 8 Small Cell Lung Carcinoma 7 Neuroblastoma 7 Glioblastoma 7 Sarcoma, Ewing 6 Rhabdomyosarcoma 6 Neoplasm Metastasis 6 Carcinoma, Non-Small-Cell Lung 6 Central Nervous System Neoplasms 5 Glioma 4 Gastrointestinal Neoplasms 4 Advanced Solid Tumors 4 Sarcoma 3 Medulloblastoma 3 Gliosarcoma 3 Brain Neoplasms 3 Astrocytoma 3 Recurrence 2 Rectal Diseases 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neoplasms by Site 2 Metastatic Pancreatic Adenocarcinoma 2 Intestinal Neoplasms 2 Intestinal Diseases 2

Interventions

pembrolizumab 5 Gemcitabine 5 Paclitaxel 4 Nivolumab 3 Fluorouracil 3 Cyclophosphamide 3 Carboplatin 3 Capecitabine 3 sargramostim 2 poly ICLC 2 fludarabine 2 Prednisone 2 Oxaliplatin 2 Dexamethasone 2 Albumin-Bound Paclitaxel 2 tegafur-gimeracil-oteracil 1 spartalizumab 1 sintilimab 1 rucaparib 1 resiquimod 1 repotrectinib 1 regorafenib 1 pralsetinib 1 olaparib 1 lenvatinib 1 dabrafenib 1 belinostat 1 balstilimab 1 Taxes 1 S 1 (combination) 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03722108 2023-10-16

REGIRI

UNICANCER

Phase 1/2 Terminated

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡